Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Inclusion Criteria: * Confirmed HIV-1 infection. * Documented level of HIV-1 RNA at initiation of antiretroviral treatments * Prior antiretroviral regimen, including at least 2 NRTIs combined to 1 PI or NNRTI or a third NRTI for at least 18 months prior to study entry. * CD4 count of 200 cells per mm3 or greater. * Viral load below 400 copies per ml within 18 months prior to entry and below 50 copies per mL at entry. * Willing to use acceptable methods of contraception Exclusion Criteria: * Previous virological failure under prior PI-based regimen. * Prior therapy in the darunavir. * HIV-2 infected patients. * Absence of documented level of HIV-1 RNA at initiation of antiretroviral treatments * Hepatitis B or C infection within 90 days prior to study entry. * Therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry. * Serious acute illness requiring systemic treatment or hospitalization in the 14 days prior to study entry. * Treatment for an active AIDS defining opportunistic infection within 30 days prior to screening * Drug or alcohol use or any dependence that would interfere with compliance. * Pregnancy or breastfeeding